Cellectar Biosciences Inc Share Price Today: Live Updates & Key Insights

Cellectar Biosciences Inc share price today is $3.22, up 1.89%. The stock opened at $3.0926 against the previous close of $3.18, with an intraday high of $3.17 and low of $3.0926.

Cellectar Biosciences Inc Share Price Chart

Cellectar Biosciences Inc

us-stock
To Invest in {{usstockname}}
us-stock

Cellectar Biosciences Inc Share Price Performance

$3.22 0.0189(1.89%) CLRB at 23 Mar 2026 12:29 PM Biotechnology
Lowest Today 3.0926
Highest Today 3.17
Today’s Open 3.0926
Prev. Close 3.18
52 Week High 20.60
52 Week Low 2.45
Day’s Range: Low 3.0926 High 3.17
52-Week Range: Low 2.45 High 20.60
1 day return -
1 Week return -2.73
1 month return -4.76
3 month return +11.88
6 month return -41.06
1 year return +734.2
3 year return +111.92
5 year return -82.88
10 year return -

Cellectar Biosciences Inc Institutional Holdings

Bleichroeder LP 2.36

Vanguard Group Inc 2.10

Vanguard Total Stock Mkt Idx Inv 1.20

Vanguard Institutional Extnd Mkt Idx Tr 0.73

Geode Capital Management, LLC 0.68

Sequoia Financial Advisors LLC 0.60

DRW Securities, LLC 0.50

Fidelity Extended Market Index 0.45

Abante Quant Value FI 0.43

Susquehanna International Group, LLP 0.29

Riverview Capital Advisers LLC 0.24

NT Ext Equity Mkt Idx Fd - L 0.16

DFA US Small Cap I 0.14

BlackRock Inc 0.11

Fidelity Series Total Market Index 0.08

Spartan Total Market Index Pool G 0.07

Blackrock Extended Mkt Fund CF 0.07

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.06

Extended Equity Market Fund K 0.06

DFA US Vector Equity Class F 0.05

Spartan Extended Market Index Pool F 0.05

Fidelity Total Market Index 0.05

NT Ext Equity Mkt Idx Fd - NL 0.05

Tower Research Capital LLC 0.04

Northern Trust Extended Eq Market Idx 0.04

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.04

UBS Group AG 0.02

Vanguard Instl Ttl Stck Mkt Idx Tr 0.02

Vanguard U.S. Eq Idx £ Acc 0.01

Morgan Stanley - Brokerage Accounts 0.01

State St US Extended Mkt Indx NL Cl C 0.01

TD Waterhouse Canada Inc 0.00

Bank of America Corp 0.00

Citigroup Inc 0.00

SBI Securities Co Ltd 0.00

Advisor Group Holdings, Inc. 0.00

JONES FINANCIAL COMPANIES LLLP 0.00

U.S. Bancorp 0.00

ACT Capital Management, LLC 0.00

Danske Bank A/S. 0.00

Cellectar Biosciences Inc Market Status

Strong Buy: 1

Buy: 1

Hold: 2

Sell: 0

Strong Sell: 0

Cellectar Biosciences Inc Fundamentals

Market Cap 13.74 M

PB Ratio 1.6344

PE Ratio 0.0

Enterprise Value 1.22 M

Total Assets 14.98 M

Volume 57474

Cellectar Biosciences Inc Company Financials

Annual Revenue FY24:null 0.0M, FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M

Annual Profit FY24:-192375 -0.2M, FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M

Annual Net worth FY24:-37983496 -38.0M, FY23:-37749931 -37.7M, FY22:-28601254 -28.6M, FY21:-23970163 -24.0M, FY20:-14756542 -14.8M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-52277 -0.1M, Q2/2025:null 0.0M, Q1/2025:-56295 -0.1M, Q3/2024:-66021 -0.1M, Q2/2024:null 0.0M

Quarterly Net worth Q3/2025:-4443877 -4.4M, Q2/2025:-5447911 -5.4M, Q1/2025:-6604029 -6.6M, Q3/2024:-14664719 -14.7M, Q2/2024:-919371 -0.9M

About Cellectar Biosciences Inc & investment objective

Company Information Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.

Organisation Biotechnology

Employees 11

Industry Biotechnology

CEO Mr. James V. Caruso

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Cellectar Biosciences Inc FAQs

What is the share price of Cellectar Biosciences Inc today?

The current share price of Cellectar Biosciences Inc is $3.22.

Can I buy Cellectar Biosciences Inc shares in India?

Yes, Indian investors can buy Cellectar Biosciences Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Cellectar Biosciences Inc shares in India?

You can easily invest in Cellectar Biosciences Inc shares from India by:

Can I buy fractional shares of Cellectar Biosciences Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Cellectar Biosciences Inc?

Cellectar Biosciences Inc has a market cap of $13.74 M.

In which sector does Cellectar Biosciences Inc belong?

Cellectar Biosciences Inc operates in the Biotechnology sector.

What documents are required to invest in Cellectar Biosciences Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Cellectar Biosciences Inc?

The PE ratio of Cellectar Biosciences Inc is N/A and the PB ratio is 1.63.